24.83 0.00 (0.00%)
After hours: 4:35PM EDT
|Bid||24.71 x 900|
|Ask||24.92 x 1400|
|Day's Range||24.52 - 25.00|
|52 Week Range||10.85 - 25.96|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.70|
Let's check out the Yahoo Finance charts of the day. Up First, Coca Cola (COKE). Shares are up .02% right now in midday trading. The beverage giant is interested in CBD, the non-psychoactive ingredient in marijuana, and is in talks with Canadian marijuana producer Aurora Cannabis to develop drinks, according to Bloomberg. Next, Teva pharmaceuticals (TEVA). Shares are up in early trade, at around 4.81%. Over the weekend the drugmaker announced the FDA approved its drug for the preventive treatment of migraines in adults. Finally Tesla (TSLA). Shares are down here around 1.01%...CEO Elon Musk weighing in on the carmaker's latest issue, responding to a customer complaint on twitter - "Sorry, we've gone from production hell to delivery logistics hell, but this problem is far more tractable. We're making rapid progress." For more on today's big stock movers check out the Final Round, live at 3:30 p.m. ET, right here on Yahoo Finance.
Prospects are looking brighter for Teva Pharmaceuticals Industries Limited (NYSE:TEVA). The company won a pair of FDA approvals in September. The big news here is the FDA approving its migraine treatment.
Teva Neuroscience Inc. plans to sublease its Overland Park headquarters to a fast-growing health IT company.
NEW YORK, NY / ACCESSWIRE / September 18, 2018 / Wall Street was cheering for Teva on Monday after the Israeli pharmaceutical giant received FDA approval finally for its migraine drug Ajovy. Shares of ...
Teva Pharmaceutical Industries Ltd. announced today the early tender results in connection with its previously announced tender offers to purchase for c
Teva Pharmaceutical Industries announced Friday evening that it had secured Food and Drug Administration approval for its new antimigraine drug, Ajovy. Teva shares were up 5% by midday Monday in New York. Novartis and Amgen won FDA approval for a similar drug in May while Eli Lilly has a competing product that might reach market soon.
While FDX stock has broken above that level again, it’s now hitting a level that’s formed as downtrend resistance. Teva (NYSE:TEVA) is off its morning gains, but is up over 2% Monday thanks to FDA approval for its migraine drug. The rejection off $25 is somewhat discouraging, but it’s positive to see Teva up over all three of its major moving averages.
Trump economic adviser Larry Kudlow suggests Trump is ready to impose tariffs on additional $200 billion worth of China-made goods. Stocks ended near their lows of the day after President Trump said there would be an announcement on trade with China after the closing bell.
Trade war fears dragged stock futures lower Monday. Broadcom received an upgrade. McDonald's dived as an analyst lowered the stock's price target.
On September 14, Teva Pharmaceutical Industries (TEVA) announced the FDA approval of Ajovy (fremanezumab), its injectable migraine drug. Following the news, a number of analysts raised their recommendations and target prices on Teva Pharmaceutical Industries.
FDA approval of Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE: TEVA )'s migraine preventive medication Ajovy led Credit Suisse to raise its price target for the stock Monday. The Analyst Credit Suisse ...
Teva Pharmaceutical Industries (TEVA) received FDA approval for its Ajovy (fremanezumab-vfrm) injectable on September 14. The chart below shows the company’s quarterly sales trend. The marketing application for Ajovy was filed by Teva in Europe in February. Teva’s (TEVA) Ajovy is an anti-CGRP (calcitonin gene-related peptide) migraine prevention treatment and offers monthly and quarterly dosage options.
Ryan McQueeney touches on the trade war's latest tariff threats and a key FDA approval for Teva Pharmaceuticals. He also highlights two surprising companies which might have a chance to profit from the marijuana boom. Later, Ryan previews Oracle and FedEx's earnings reports.
On September 14, Teva Pharmaceutical Industries (TEVA) announced that the FDA had approved fremanezumab, its long-awaited migraine drug. The FDA had delayed the approval for the drug, which had been expected in June, due to a warning letter to Teva’s manufacturing partner Celltrion. The FDA provided a PDUFA (Prescription Drug User Fee Act) date of September 16.
American depository receipts jumped in morning trading on Monday, Sept. 17, following the news late Friday that the company had clinched the U.S. Food and Drug Administration's nod for its migraine drug. It is the second anti-calcitonin gene-related peptide (CGRP) drug approved by the agency to prevent migraines, after Amgen Inc. CGRP is thought to play a key role in causing migraine headaches.
Teva Pharmaceutical Industries Ltd. shares surged nearly 7% in Monday premarket trade after the company's migraine therapy, intended to prevent chronic attacks of head pain along with other severe, disabling symptoms, was approved by the U.S. Food and Drug Administration. The therapy, Ajovy, is administered as an injection, using a prefilled syringe, and can be dosed on a quarterly or monthly basis. The monthly dose will cost $575 per dose and the quarterly dose will cost $1,725, Teva said, meaning the product's total yearly cost will be about $6,900 per year irrespective of dose. The pricing figures released by Teva refer to the therapy's wholesale acquisition cost, or the price a drugmaker offers wholesalers, from which discounts are typically taken. About 38 million Americans, or 12% of the population, experience migraines, and though the treatment landscape has been sparse so far, it is poised to become increasingly competitive. Another preventative therapy, from Amgen Inc. and Novartis AG [S: nvs] was approved by the FDA in May, and the companies cited the same price tag, or $6,900. A FDA decision for another drug in this class, from Eli Lilly & Co. , is expected in the near future as well. For the beleaguered Teva, the new approval is a "clear positive," said J.P. Morgan analyst Chris Schott, though he noted "the highly competitive dynamics in the space with Amgen, Teva and Lilly all launching within six months of each other and with relatively limited differentiation among agents." Schott expects Teva's migraine therapy could sell about $150 million next year and as much as $600 million by 2022; even so, he sees "few growth drivers or pipeline assets beyond Ajovy" given generic competition for the company's flagship multiple sclerosis medication and challenging conditions for generic drugs. Shares of the U.S.-listed Teva have surged 20.6% year-to-date, while the S&P 500 has risen 8.7% and the Dow Jones Industrial Average has lifted 5.8%.
Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE: TEVA ) — has struggled amid sagging sales of its blockbuster multiple sclerosis treatment Capaxone due to a generic launch in 2017 and its debt burden ...
Teva Pharmaceutical Industries Ltd. climbed as much as 7.4 percent in early U.S. trading after FDA approval of its migraine drug, Ajovy, surprised the Street. The medicine is the second of its kind, behind Amgen’s Aimovig, and has the potential to reach sales of $1 billion in four years, according to BTIG analyst Timothy Chiang. “Teva continues to move in the right direction, now run by strong management, which is implementing deep cost reductions.
Teva Pharmaceutical Industries Ltd. won U.S. regulatory approval to sell a new treatment for migraines, a key part of the company’s turnaround strategy. The U.S. Food and Drug Administration approved Ajovy, an injection administered every few months to relieve migraines in adults, the Israeli drugmaker said in a statement late Friday. More than 36 million people in the U.S. suffer from these debilitating episodes, and the medicine could generate around $500 million of sales by 2022, according to analyst estimates compiled by Bloomberg.